Earnings ·
QuidelOrtho Corporation reported second quarter 2026 results ending June 28, 2026, with total revenue of $631 million…
QDELQuidelOrtho Corp
QuidelOrtho Corporation reported second quarter 2026 results ending June 28, 2026, with total revenue of $631 million, up 3% year-over-year. The company posted a GAAP net loss of $93 million and adjusted diluted EPS of $0.13. Driven by pricing changes in China and a softer respiratory environment, QuidelOrtho significantly lowered its full-year 2026 guidance: total revenue is now projected at $2.52–$2.60 billion (down from $2.70–$2.75 billion), adjusted EBITDA at $540–$560 million (down from $615–$630 million), and adjusted diluted EPS at $0.65–$0.90 (down from $1.80–$2.00). The company also withdrew its free cash flow guidance. QuidelOrtho operates in the medical diagnostics industry, providing clinical chemistry, immunoassay, immunohematology, and molecular testing solutions.